EconRx

Aducanumab (brand name Aduhelm) drew headlines when it was approved by the FDA in 2021 against the recommendations of the FDA advisory committee. Today it's almost commercially dead. On this episode are joined by P4 student Ise Brockmann to dive into aducanumab's story. email: econrxpodcast@gmail.com Twitter/Instagram: @EconRx LinkedIn: www.linkedin.com/company/econrx Website: https://econrx.libsyn.com/

Capping patient out-of-pocket costs for insulin has been a popular move for legislators, most recently by the US House. On this episode we weigh the Pros, Cons, and viral reactions to this move including lowering vs. shifting costs, ADA guidelines, and political theater. email: econrxpodcast@gmail.com Twitter/Instagram: @EconRx LinkedIn: www.linkedin.com/company/econrx Website: https://econrx.libsyn.com/

After explaining a HORRENDOUS mistake made recently by the NABP and the oversight of NAPLEX testing that affected one of our own, we decided it's high time we dove into the controversy around the use of ivermectin against COVID-19. Social media and mainstream news can be confusing, so we tried to summarize while sticking to what is known. If we missed something, please let us know! email: econrxpodcast@gmail.com Twitter/Instagram: @EconRx LinkedIn: www.linkedin.com/company/econrx Website: https://econrx.libsyn.com/

On this episode we were blessed to have on Kyle McCormick, owner/operator of Blueberry Pharmacy, to explain his unique (but traditionally familiar) business model. Blueberry operates on a cost-plus model and DOES NOT ACCEPT INSURANCE. Crazy? Maybe not. Kyle explains why he thinks we need different payment systems for cheap generics than expensive brand names, circumventing PBMs when they aren't necessary. https://blueberrypharmacy.com/ email: econrxpodcast@gmail.com Twitter/Instagram: @EconRx LinkedIn: www.linkedin.com/company/econrx Website: https://econrx.libsyn.com/

The Twittersphere recently noticed that quoted savings on Amazon Pharmacy are a little bit unrealistic. On this episode we break down how a pharmacy's "Usual & Customary" price SHOULD be calculated, what it is used for, and what Amazon's crazy numbers say about their pharmacy business model. email: econrxpodcast@gmail.com Twitter/Instagram: @EconRx LinkedIn: www.linkedin.com/company/econrx Website: https://econrx.libsyn.com/

The COVID-19 pandemic highlighted many weaknesses in the US Drug Supply Chain's dependence on foreign production (similar to toilet paper, masks, etc.). The Biden White House recently announced plans to address supply chain weaknesses to prevent future shortages due to overseas dependence.   email: econrxpodcast@gmail.com Twitter/Instagram: @EconRx LinkedIn: www.linkedin.com/company/econrx Website: https://econrx.libsyn.com/

After a brief hiatus we are back in the studio! Everyone has important life updates to share, Aaron has some interesting learning points about Medicaid rebates, Ryan explains DIR fees, and we check back in with GoodRx's recent stock price woes. email: econrxpodcast@gmail.com Twitter/Instagram: @EconRx LinkedIn: www.linkedin.com/company/econrx Website: https://econrx.libsyn.com/

Since we have had guests on for the last few episodes, we wanted to take some time to cover some recent topics that have come up in the first quarter of 2021. Chosen topics: Aaron - COVID vaccine hesitancy Ryan - Inclusion of indications on prescriptions Josh - Stimulus and the child tax credit email: econrxpodcast@gmail.com Twitter/Instagram: @EconRx LinkedIn: www.linkedin.com/company/econrx Website: https://econrx.libsyn.com/

We are beyond excited to welcome AJ Rivosecchi, PharmD onto the podcast to talk about Kit Check. A company that started as a tool for managing hospital medication inventory is growing to address drug diversion and spend optimization. Along the way they may even change industry standards for the pharmaceutical industry. email: econrxpodcast@gmail.com Twitter/Instagram: @EconRx LinkedIn: www.linkedin.com/company/econrx Website: https://econrx.libsyn.com/ kitcheck.com

Ever been to an independent pharmacy? One with a soda fountain and ice cream bar? The level of service provided is a far cry more personal than the usual retail-pharmacy experience. Don't believe us? Hear it here straight from the Roche's mouth. Bad joke, sorry. But seriously, give @b_roche a listen and get yourself some Red Oil. email: econrxpodcast@gmail.com Twitter/Instagram: @EconRx LinkedIn: www.linkedin.com/company/econrx Website: https://econrx.libsyn.com/ rochepharmacyinc.com

On this episode we are joined by the one and only Mike Corvino of the @CorConsultRx podcast to talk about recent attacks on the 340B program. We outline, with a provider's perspective, how the 340B program helps provide care for underserved patients. We also explain how aspects of the program are seen as abuse or exploitation by some Industry stakeholders. email: econrxpodcast@gmail.com Twitter/Instagram: @EconRx LinkedIn: www.linkedin.com/company/econrx Website: https://econrx.libsyn.com/

2020 IS OVER!!! Well, almost anyway. Before we end the weirdest year ever, we wanted to give you one more episode. We discussed a bunch of random stuff like the supreme court and vaccine approvals (YAY!). We also discussed formularies and how they work. Jan 1 is nigh and formulary changes come with it. email: econrxpodcast@gmail.com Twitter/Instagram: @EconRx LinkedIn: www.linkedin.com/company/econrx Website: https://econrx.libsyn.com/

Amazon is officially entering the mail order pharmacy space. Is this going to be a huge market-up-ending disruption like every other space the online retail giant enters? Hard to say at this point, but it sure is a fun topic to talk about.    email: econrxpodcast@gmail.com Twitter/Instagram: @EconRx LinkedIn: www.linkedin.com/company/econrx Website: https://econrx.libsyn.com/

On this episode we were able to fit in two topics! First, we gave an update of the status of COVID-19 vaccines following some exciting news from Pfizer this week. We then began to discuss challenges around biosimilar adoption and interchangeability. What's a biosimilar? Why should you care? Guess you gotta listen to find out... email: econrxpodcast@gmail.com Twitter/Instagram: @EconRx LinkedIn: www.linkedin.com/company/econrx Website: https://econrx.libsyn.com/

On Oct 6, 2020 JAMA published an article by R. Sachs (link below) that explains the impossible position different pieces of Federal legislation have created for State Medicaid programs. In this episode we break down the article and why it provides some insight into broader problems in prescription drug reimbursement. source article email: econrxpodcast@gmail.com Twitter/Instagram: @EconRx LinkedIn: www.linkedin.com/company/econrx Website: https://econrx.libsyn.com/

On September 13th the White House published the "Executive Order on Lowering Drug Prices by Putting America First." EconRx breaks down the who, what, where, why, and HOW of this latest attempt to address rising drug prices. Spoiler: It might not do anything at all... email: econrxpodcast@gmail.com Twitter/Instagram: @EconRx LinkedIn: www.linkedin.com/company/econrx Website: https://econrx.libsyn.com/

Ever wonder how private health insurance became so common in the US? Or why it's most commonly given as a benefit from an employer? We break down the history of how this came to be and what that means for patients today. email: econrxpodcast@gmail.com Twitter/Instagram: @EconRx LinkedIn: www.linkedin.com/company/econrx Website: https://econrx.libsyn.com/

This week the Trio break down GoodRx and the recent news that the prescription discount company wants to go public. How does a company that saves patients money...make money? The answer is a little frustrating to some.  email: econrxpodcast@gmail.com Twitter/Instagram: @EconRx LinkedIn: www.linkedin.com/company/econrx Website: https://econrx.libsyn.com/

Did you know Medicare is the single biggest provider of health insurance in the US? Now you do. You're welcome. Josh and Aaron give an overview of this enormous government program and discuss its ups and downs.  email: econrxpodcast@gmail.com Twitter/Instagram: @EconRx LinkedIn: www.linkedin.com/company/econrx Website: https://econrx.libsyn.com/

THE BOYS ARE BACK IN TOWN...or at least able to record in person for a change. On this episode we are joined by Mike Corvino of CorConsult Rx to talk about telehealth changes, billing, and its potential for the future of healthcare. We went on some long winding tangents and had a LOT of fun doing it. Enjoy! email: econrxpodcast@gmail.com Twitter/Instagram: @EconRx LinkedIn: www.linkedin.com/company/econrx Website: https://econrx.libsyn.com/

We took another side session to talk about the current state of the race to a vaccine for COVID-19. Vaccine by October? Maybe, but that might not mean what you think it means. Initiate warp drive! -And other Star Trek references. We broke 1 hour for the first time (oops), but if you're curious about the chances of a vaccine getting us out of this crazy time we are in, the time is well worth it.  email: econrxpodcast@gmail.com Twitter/Instagram: @EconRx LinkedIn: www.linkedin.com/company/econrx Website: https://econrx.libsyn.com/

On this episode the guys try to do the opposite of a deep-dive...a belly flop...in the kiddie pool. In the first part of our "Health Insurance" series, Aaron and Ryan give a broad overview of health insurance (with a few tangents along the way). Josh provided a small cameo explaining the Indian Health Service that will definitely be expanded into a full episode soon. Enjoy! email: econrxpodcast@gmail.com Twitter/Instagram: @EconRx LinkedIn: www.linkedin.com/company/econrx Website: https://econrx.libsyn.com/

This episode tries out a different format from our regularly scheduled programming. We sit down and discuss (and sometimes rant about) our thoughts about Gilead's $3k price tag announcement for remdesivir. What was supposed to be a quick discussion of a current event quickly devolved into broader discussions about drug pricing, patent law, and public opinion.   email: econrxpodcast@gmail.com Twitter/Instagram: @EconRx LinkedIn: www.linkedin.com/company/econrx

In this episode, Aaron, Ryan, and Josh introduce themselves and the podcast. They talk about where future episodes might lead and some other random stuff. They finish up by covering some basic economic principles: - Incentives - Scarcity - Elasticity email: econrxpodcast@gmail.com Twitter/Instagram: @EconRx LinkedIn: www.linkedin.com/company/econrx